vs
NEOGENOMICS INC（NEO）与Sotera Health Co（SHC）财务数据对比。点击上方公司名可切换其他公司
Sotera Health Co的季度营收约是NEOGENOMICS INC的1.6倍（$303.4M vs $186.7M），Sotera Health Co净利率更高（11.5% vs -57.9%，领先69.3%），NEOGENOMICS INC同比增速更快（11.1% vs 4.6%），过去两年Sotera Health Co的营收复合增速更高（10.6% vs 6.5%）
新基因组公司（NeoGenomics）是美国一家经CLIA认证的临床实验室企业，提供药企服务与信息服务，专注于癌症基因诊断检测，旗下检测服务涵盖细胞遗传学、荧光原位杂交（FISH）、流式细胞术、免疫组化、解剖病理学及分子遗传学等多个领域，为肿瘤相关诊断提供专业支持。
Sotera Health Co是全球领先的医疗安全解决方案提供商，面向医疗器械厂商、制药企业、食品及消费品公司提供灭菌服务、实验室分析检测与合规咨询支持，帮助客户满足监管要求，保障上市产品的使用安全。
NEO vs SHC — 直观对比
营收规模更大
SHC
是对方的1.6倍
$186.7M
营收增速更快
NEO
高出6.5%
4.6%
净利率更高
SHC
高出69.3%
-57.9%
两年增速更快
SHC
近两年复合增速
6.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $186.7M | $303.4M |
| 净利润 | $-108.0M | $34.8M |
| 毛利率 | 43.3% | 54.7% |
| 营业利润率 | — | 23.2% |
| 净利率 | -57.9% | 11.5% |
| 营收同比 | 11.1% | 4.6% |
| 净利润同比 | 42.0% | 182.8% |
| 每股收益（稀释后） | $-0.13 | $0.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NEOSHC
| Q1 26 | $186.7M | — | ||
| Q4 25 | $190.2M | $303.4M | ||
| Q3 25 | $187.8M | $311.3M | ||
| Q2 25 | $181.3M | $294.3M | ||
| Q1 25 | $168.0M | $254.5M | ||
| Q4 24 | $172.0M | $290.2M | ||
| Q3 24 | $167.8M | $285.5M | ||
| Q2 24 | $164.5M | $276.6M |
净利润NEOSHC
| Q1 26 | $-108.0M | — | ||
| Q4 25 | — | $34.8M | ||
| Q3 25 | $-27.1M | $48.4M | ||
| Q2 25 | $-45.1M | $8.0M | ||
| Q1 25 | $-25.9M | $-13.3M | ||
| Q4 24 | — | $12.3M | ||
| Q3 24 | $-17.7M | $17.0M | ||
| Q2 24 | $-18.6M | $8.8M |
毛利率NEOSHC
| Q1 26 | 43.3% | — | ||
| Q4 25 | 43.8% | 54.7% | ||
| Q3 25 | 42.8% | 57.0% | ||
| Q2 25 | 42.6% | 56.6% | ||
| Q1 25 | 43.6% | 53.2% | ||
| Q4 24 | 44.9% | 56.6% | ||
| Q3 24 | 44.6% | 55.4% | ||
| Q2 24 | 44.1% | 55.2% |
营业利润率NEOSHC
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | 23.2% | ||
| Q3 25 | -14.4% | 23.4% | ||
| Q2 25 | -26.3% | 6.4% | ||
| Q1 25 | -16.6% | -5.8% | ||
| Q4 24 | -10.7% | 30.0% | ||
| Q3 24 | -12.6% | 28.2% | ||
| Q2 24 | -13.3% | 27.8% |
净利率NEOSHC
| Q1 26 | -57.9% | — | ||
| Q4 25 | — | 11.5% | ||
| Q3 25 | -14.4% | 15.5% | ||
| Q2 25 | -24.9% | 2.7% | ||
| Q1 25 | -15.4% | -5.2% | ||
| Q4 24 | — | 4.2% | ||
| Q3 24 | -10.5% | 6.0% | ||
| Q2 24 | -11.3% | 3.2% |
每股收益（稀释后）NEOSHC
| Q1 26 | $-0.13 | — | ||
| Q4 25 | — | $0.12 | ||
| Q3 25 | — | $0.17 | ||
| Q2 25 | — | $0.03 | ||
| Q1 25 | — | $-0.05 | ||
| Q4 24 | — | $0.05 | ||
| Q3 24 | — | $0.06 | ||
| Q2 24 | — | $0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $146.1M | $344.6M |
| 总债务越低越好 | — | $2.1B |
| 股东权益账面价值 | $828.8M | $606.0M |
| 总资产 | $1.3B | $3.3B |
| 负债/权益比越低杠杆越低 | — | 3.53× |
8季度趋势，按日历期对齐
现金及短期投资NEOSHC
| Q1 26 | $146.1M | — | ||
| Q4 25 | $159.6M | $344.6M | ||
| Q3 25 | $164.1M | $299.2M | ||
| Q2 25 | $154.7M | $332.4M | ||
| Q1 25 | $346.2M | $304.4M | ||
| Q4 24 | $367.0M | $277.2M | ||
| Q3 24 | $362.0M | $306.7M | ||
| Q2 24 | $355.1M | $246.1M |
总债务NEOSHC
| Q1 26 | — | — | ||
| Q4 25 | $341.9M | $2.1B | ||
| Q3 25 | — | $2.1B | ||
| Q2 25 | — | $2.2B | ||
| Q1 25 | — | $2.2B | ||
| Q4 24 | $541.1M | $2.2B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B |
股东权益NEOSHC
| Q1 26 | $828.8M | — | ||
| Q4 25 | $836.6M | $606.0M | ||
| Q3 25 | $838.3M | $550.5M | ||
| Q2 25 | $854.0M | $511.3M | ||
| Q1 25 | $888.3M | $414.1M | ||
| Q4 24 | $902.3M | $404.9M | ||
| Q3 24 | $908.2M | $470.2M | ||
| Q2 24 | $915.9M | $422.8M |
总资产NEOSHC
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.4B | $3.3B | ||
| Q3 25 | $1.4B | $3.2B | ||
| Q2 25 | $1.4B | $3.2B | ||
| Q1 25 | $1.6B | $3.1B | ||
| Q4 24 | $1.6B | $3.1B | ||
| Q3 24 | $1.6B | $3.1B | ||
| Q2 24 | $1.6B | $3.1B |
负债/权益比NEOSHC
| Q1 26 | — | — | ||
| Q4 25 | 0.41× | 3.53× | ||
| Q3 25 | — | 3.89× | ||
| Q2 25 | — | 4.34× | ||
| Q1 25 | — | 5.36× | ||
| Q4 24 | 0.60× | 5.49× | ||
| Q3 24 | — | 4.73× | ||
| Q2 24 | — | 5.26× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-8.1M | $103.1M |
| 自由现金流经营现金流 - 资本支出 | — | $52.4M |
| 自由现金流率自由现金流/营收 | — | 17.3% |
| 资本支出强度资本支出/营收 | — | 16.7% |
| 现金转化率经营现金流/净利润 | — | 2.96× |
| 过去12个月自由现金流最近4个季度 | — | $149.2M |
8季度趋势，按日历期对齐
经营现金流NEOSHC
| Q1 26 | $-8.1M | — | ||
| Q4 25 | $1.3M | $103.1M | ||
| Q3 25 | $8.9M | $71.2M | ||
| Q2 25 | $20.3M | $57.4M | ||
| Q1 25 | $-25.3M | $55.5M | ||
| Q4 24 | $9.8M | $55.7M | ||
| Q3 24 | $9.2M | $97.5M | ||
| Q2 24 | $13.9M | $61.3M |
自由现金流NEOSHC
| Q1 26 | — | — | ||
| Q4 25 | $-6.5M | $52.4M | ||
| Q3 25 | $570.0K | $35.0M | ||
| Q2 25 | $14.0M | $26.2M | ||
| Q1 25 | $-29.8M | $35.6M | ||
| Q4 24 | $-1.8M | $-10.2M | ||
| Q3 24 | $-1.6M | $61.1M | ||
| Q2 24 | $814.0K | $19.4M |
自由现金流率NEOSHC
| Q1 26 | — | — | ||
| Q4 25 | -3.4% | 17.3% | ||
| Q3 25 | 0.3% | 11.2% | ||
| Q2 25 | 7.7% | 8.9% | ||
| Q1 25 | -17.8% | 14.0% | ||
| Q4 24 | -1.0% | -3.5% | ||
| Q3 24 | -0.9% | 21.4% | ||
| Q2 24 | 0.5% | 7.0% |
资本支出强度NEOSHC
| Q1 26 | — | — | ||
| Q4 25 | 4.1% | 16.7% | ||
| Q3 25 | 4.4% | 11.6% | ||
| Q2 25 | 3.5% | 10.6% | ||
| Q1 25 | 2.7% | 7.8% | ||
| Q4 24 | 6.7% | 22.7% | ||
| Q3 24 | 6.4% | 12.7% | ||
| Q2 24 | 8.0% | 15.2% |
现金转化率NEOSHC
| Q1 26 | — | — | ||
| Q4 25 | — | 2.96× | ||
| Q3 25 | — | 1.47× | ||
| Q2 25 | — | 7.21× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.52× | ||
| Q3 24 | — | 5.73× | ||
| Q2 24 | — | 7.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NEO
暂无分部数据
SHC
| Transferred At Point In Time | $198.4M | 65% |
| Nelson Labs | $55.2M | 18% |
| Nordion | $49.8M | 16% |
